| Name | Title | Contact Details |
|---|---|---|
Aymii Couzelis |
Chief Information Officer | Profile |
Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to certain tissues, de-target other tissues, and improve its safety. This has resulted in over twenty (20) patents related to the use of AAV for therapeutic uses. Dr. Samulski continues to lead innovation in the field of vector optimization and AAV re-engineering.
RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.
Transave is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CARIS MPI is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VGXI is a Spring, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.